Table 3. Pharmacokinetic parameters of chidamide.
| Treatment | Dose | Cmax (ng/mL) | AUC0−t (h×ng/mL) | AUC0−inf (h×ng/mL) | Tmax (h) [median (range)] | t1/2 (h) |
| CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; Cmax, peak plasma concentration; AUC0−t, area under the curve up to the last measurable time point; AUC0−inf, area under the curve from time zero to infinity; Tmax, the time of maximum plasma concentration; t1/2, half-life. | ||||||
Chidamide (
)
|
20 mg (n=6) | 50.1±35.2 | 835.3±275.6 | 879.2±287.4 | 6.0 (1.0, 8.0) | 15.8±5.1 |
| 25 mg (n=3) | 61.2±7.9 | 1,278.0±399.0 | 1,344.8±428.3 | 2.0 (1.0, 8.0) | 15.2±2.2 | |
| 30 mg (n=3) | 82.6±61.3 | 1,311.4±470.9 | 1,412.1±504.4 | 8.0 (2.0, 8.0) | 20.2±3.9 | |
| 35 mg (n=3) | 125.3±94.4 | 1,668.0±161.0 | 1,797.1±210.7 | 8.0 (2.0, 8.0) | 19.1±12.0 | |
| Grand mean | − | − | − | 8.0 (1.0, 8.0) | 17.2±5.9 | |
| Chidamide +
CHOP ( 
)
|
20 mg (n=6) | 42.2±10.7 | 811.1±289.3 | 853.2±297.9 | 8.0 (2.0, 8.0) | 14.1±3.9 |
| 25 mg (n=3) | 52.5±29.7 | 1,056.3±573.2 | 995.6±777.4 | 8.0 (8.0, 12.0) | 15.3±3.9 | |
| 30 mg (n=3) | 96.0±20.5 | 1,790.3±150.7 | 1,938.3±175.7 | 8.0 (4.0, 8.0) | 20.2±4.5 | |
| 35 mg (n=3) | 103.8±29.5 | 1,527.7±125.4 | 1,616.1±93.2 | 2.0 (1.0, 8.0) | 13.3±0.4 | |
| Grand mean | − | − | − | 8.0 (1.0, 12.0) | 15.7±5.6 | |